INCY and NBIX Outshine AMGN According to Trefis Model

The Trefis model suggests that INCY and NBIX are more attractive investments than Amgen stock.

Incyte Corp (INCY) and Neurocrine Biosciences Inc (NBIX) have outperformed Amgen Inc (AMGN) in terms of consensus earnings per share estimates, according to the Trefis model. INCY has a 10% higher consensus EPS estimate compared to AMGN, while NBIX's is 21% higher.

The model also shows that both companies have a higher growth rate than Amgen, with INCY at 11.8% and NBIX at 14.1%. These numbers indicate that investors may be better off looking into these two stocks instead of Amgen for potential returns.